<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03112980</url>
  </required_header>
  <id_info>
    <org_study_id>DEDICATE</org_study_id>
    <secondary_id>DEDICATE - DZHK 6</secondary_id>
    <nct_id>NCT03112980</nct_id>
  </id_info>
  <brief_title>Randomized Trial of TAVI vs. SAVR in Patients With Severe Aortic Valve Stenosis at Intermediate Risk of Mortality</brief_title>
  <acronym>DEDICATE</acronym>
  <official_title>Randomized, Multi-Center, Event-Driven Trial of TAVI Versus SAVR in Patients With Symptomatic Severe Aortic Valve Stenosis and Intermediate Risk of Mortality, as Assessed by STS-Score - DEDICATE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized controlled, multi-center trial randomizing patients with symptomatic severe aortic
      stenosis at low to intermediate operative risk of mortality, as assessed by the
      STS-PROM-Score, in a 1:1 fashion to transcatheter aortic valve implantation (TAVI) or
      surgical aortic valve replacement (SAVR) to test, whether TAVI is non-inferior to SAVR
      regarding short and long-term mortality (1 and 5 year).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is unclear, what the best therapeutic strategy in patients with symptomatic aortic valve
      stenosis at intermediate risk of perioperative mortality is. While surgical aortic valve
      replacement (SAVR) is still considered standard of care in low to intermediate risk patients,
      minimal-invasive transcatheter aortic valve implantation (TAVI) has been shown to be safe and
      effective in patients deemed inoperable or at high risk of perioperative mortality.
      Meanwhile, a paradigm-shift in TAVI from inoperable and high-risk towards intermediate risk
      patients has already begun, despite of lacking evidence in this field.

      The DEDICATE-trial is designed as a prospectively randomized (1:1), multi-center,
      comparator-controlled interventional trial to investigate whether transcatheter aortic valve
      implantation (TAVI) is non-inferior - as measured by all-cause mortality after 1 and 5 years
      - compared to surgical aortic valve replacement (SAVR) in the treatment of patients with
      symptomatic severe aortic stenosis at low to intermediate operative risk of mortality, as
      assessed by the Society of Thoracic Surgeons Predicted Risk of Mortality (STS-PROM)-Score.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 10, 2017</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Five years after last patient in</time_frame>
    <description>Efficacy endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>after at least one year of follow-up after last patient in and 196 deaths of any cause</time_frame>
    <description>Safety endpoint (event driven)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Freedom from cardiovascular mortality</measure>
    <time_frame>Five years after last patient in</time_frame>
    <description>will be assessed at every study visit and compared between TAVI and SAVR groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from the composite of all-cause mortality and stroke</measure>
    <time_frame>Five years after last patient in</time_frame>
    <description>will be assessed at every study visit and compared between TAVI and SAVR groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from myocardial infarction</measure>
    <time_frame>Five years after last patient in</time_frame>
    <description>will be assessed at every study visit and compared between TAVI and SAVR groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from stroke</measure>
    <time_frame>Five years after last patient in</time_frame>
    <description>will be assessed at every study visit and compared between TAVI and SAVR groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from major or life-threatening / disabling bleeding</measure>
    <time_frame>Five years after last patient in</time_frame>
    <description>will be assessed at every study visit and compared between TAVI and SAVR groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from acute kidney injury</measure>
    <time_frame>Five years after last patient in</time_frame>
    <description>will be assessed at every study visit and compared between TAVI and SAVR groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from vascular access site and access-related complications</measure>
    <time_frame>Five years after last patient in</time_frame>
    <description>will be assessed at every study visit and compared between TAVI and SAVR groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from conduction disturbances and arrhythmias, need for permanent pacemaker implantation</measure>
    <time_frame>Five years after last patient in</time_frame>
    <description>will be assessed at every study visit and compared between TAVI and SAVR groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from residual aortic regurgitation ≥ moderate</measure>
    <time_frame>Five years after last patient in</time_frame>
    <description>will be assessed at every study visit and compared between TAVI and SAVR groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite device success</measure>
    <time_frame>Five years after last patient in</time_frame>
    <description>Number of participants with freedom from procedural mortality and correct positioning of a single transcatheter heart valve (THV) in the proper position with intended performance (no prosthesis- patient mismatch and mean aortic valve gradient &lt;20 mmHg or peak velocity &lt;3 m/s, AND no moderate or severe prosthetic valve regurgitation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite early safety</measure>
    <time_frame>within first 30 days after procedure</time_frame>
    <description>Number of participants dying and/or number of participants with stroke (disabling and non-disabling), and/or life-threatening bleeding and/or acute kidney injury stages 2/3 and/or coronary artery obstruction requiring Intervention and/or major vascular complication and/or valve-related dysfunction requiring repeat procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite clinical efficacy</measure>
    <time_frame>within first 30 days after procedure</time_frame>
    <description>Number or participants dying and/or number of participants with stroke (disabling and non-disabling) and/or rehospitalisation for worsening heart failure or valve-related symptoms and/or New York Heart Association functional class (NYHA) III or IV and/or valve-related dysfunction (mean aortic valve gradient &gt;20 mmHg, effective orifice area (EOA) &lt;0.9-1.1 cm2 and/or Doppler Velocity Index (DVI) &lt;0. 35 m/s, AND/OR moderate or severe prosthetic valve regurgitation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from prosthetic valve dysfunction</measure>
    <time_frame>Five years after last patient in</time_frame>
    <description>will be assessed at every study visit and compared between TAVI and SAVR groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from prosthetic aortic valve endocarditis</measure>
    <time_frame>Five years after last patient in</time_frame>
    <description>will be assessed at every study visit and compared between TAVI and SAVR groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from the composite time-related valve safety</measure>
    <time_frame>Five years after last patient in</time_frame>
    <description>Number of participants with structural valve deterioration (including repeat procedures, prosthetic valve endocarditis and/or thrombosis) and/or number of participants with thromboembolic events (stroke) and/or Valve Academic Research Consortium (VARC-2) bleeding (unless clearly unrelated to valve therapy).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life measures</measure>
    <time_frame>Five years after last patient in</time_frame>
    <description>Number of participants with reduced quality of life measures after valve replacement as compared to baseline levels prior to valve-replacement, assessed using EuroQol five dimensions (EQ-5D) questionnaire and/or Barthel Index and/or center for epidemiologic studies depression (CES-D) Scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health economic analysis</measure>
    <time_frame>Five years after last patient in</time_frame>
    <description>Incremental cost-effectiveness of TAVI compared to surgical valve replacement, by using quality adjusted life years (QALYs).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1600</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>Transcatheter aortic valve implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transcatheter aortic valve implantation (TAVI) using the most appropriate CE (Conformité Européene)-marked device available, with a minimum demand of experience of 30 implanted devices/type per center.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgical aortic valve replacement</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Surgical aortic valve replacement (SAVR) with free choice of surgical bioprosthesis and free choice of surgical access according to the surgeon's preference.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcatheter aortic valve implantation</intervention_name>
    <description>(TAVI)</description>
    <arm_group_label>Transcatheter aortic valve implantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgical aortic valve replacement</intervention_name>
    <description>(SAVR)</description>
    <arm_group_label>Surgical aortic valve replacement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Heart team consensus that TAVI and SAVR are both medically justified and advisable
             based on:

               1. Degenerative aortic valve stenosis with echocardiographically derived criteria:

                    -  Mean gradient &gt;40 mmHg or

                    -  Jet velocity greater than 4.0 m/s or

                    -  Aortic valve area (AVA) of &lt; 1.0 cm2 (indexed effective orifice area &lt;
                       0.6cm2/m2).

               2. Patient is symptomatic from his/her aortic valve stenosis

                    -  New York Heart Association Functional Class ≥ II or

                    -  Angina pectoris or

                    -  Syncope.

               3. Patient is classified as intermediate risk patient according to the current
                  version of the STS-score (risk model for operative mortality: 2-6%,
                  http://riskcalc.sts.org/stswebriskcalc/)

               4. A transfemoral or alternative (e.g. transapical, transaortic, transaxillary)
                  access for TAVI seems feasible. Centers should follow a &quot;transfemoral first&quot;
                  strategy for the primary route of access; however, other routes of access are
                  also allowed, as decided by local heart team consensus.

          2. Patient has provided written informed consent to participate in the trial.

          3. Ability of the patient to understand the patient information and to personally sign
             and date the informed consent to participate in the study, before performing any study
             related procedures.

          4. The patient agrees to undergo SAVR, if randomized to control treatment.

          5. The patient and the treating physician agree that the patient will return for all
             required post-procedure follow-up visits.

          6. Patients aged 18 to 85 years.

          7. Male patients or females who are postmenopausal defined as no menses for 12 months
             without an alternative medical cause.

        Exclusion Criteria:

          1. Aortic valve is a congenital unicuspid or congenital bicuspid valve, or is
             non-calcified

          2. Untreated clinically significant coronary artery disease considered a contraindication
             to an isolated aortic valve procedure (TAVI or SAVR) according to heart team consensus

          3. Previous cardiac surgery

          4. Any percutaneous coronary intervention performed within 1 month prior to the study
             procedure

          5. Untreated severe mitral or tricuspid regurgitation

          6. Untreated severe mitral stenosis

          7. Hemodynamic instability requiring inotropic support or mechanical circulatory support

          8. Ischemic stroke or intracranial bleeding within 1 month

          9. Severe ventricular dysfunction with left ventricular ejection fraction &lt; 20% as
             measured by resting echocardiogram

         10. Hypertrophic obstructive cardiomyopathy or severe basal septal hypertrophy with
             outflow gradient

         11. Echocardiographic evidence of an intracardiac mass, thrombus, vegetation or
             endocarditis

         12. Any other condition considered a contraindication for an isolated aortic valve
             procedure

         13. Symptomatic carotid or vertebral artery disease

         14. Expected life expectancy &lt; 12 months due to associated non-cardiac comorbidities

         15. Currently participating in another investigational drug or device trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Blankenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitäres Herzzentrum Hamburg, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jochen Cremer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Schleswig-Holstein, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Moritz Seiffert, MD</last_name>
    <phone>+49 (0) 40 7410 53979</phone>
    <email>m.seiffert@uke.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stefan Blankenberg, MD</last_name>
    <phone>+49 (0) 40 7410 53972</phone>
    <email>s.blankenberg@uke.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitäts-Herzzentrum Freiburg-Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriele Lechner</last_name>
      <email>gabriele.lechner@universitaets-herzzentrum.de</email>
    </contact>
    <contact_backup>
      <last_name>Monika Bockstatt</last_name>
      <email>monika.bockstatt@universitaets-herzzentrum.de</email>
    </contact_backup>
    <investigator>
      <last_name>Franz Josef Neumann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Holger Schröfel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin (Campus Benjamin-Franklin)</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anika Maiwald</last_name>
      <email>anika.maiwald@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Steinbeck</last_name>
      <email>lisa.steinbeck@charite.de</email>
    </contact_backup>
    <investigator>
      <last_name>Ulf Landmesser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Volkmar Falk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin (Campus Mitte)</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Berg</last_name>
      <email>christina.berger@charite.de</email>
    </contact>
    <investigator>
      <last_name>Karl Stangl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Volkmar Falk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin (Campus Virchow)</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Gaulhofer</last_name>
      <email>christina.gaulhofer@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Jasmin Radenkovic</last_name>
      <email>jasmin.radenkovic@charite.de</email>
    </contact_backup>
    <investigator>
      <last_name>Burkert Pieske, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monika Post</last_name>
      <email>post@dhzb.de</email>
    </contact>
    <investigator>
      <last_name>Volkmar Falk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vivantes Friedrichshain</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martina Gregor</last_name>
      <email>martina.gregor@vivantes.de</email>
    </contact>
    <investigator>
      <last_name>Stephan Kische, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vivantes Humboldt Kliniken</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martina Gregor</last_name>
      <email>martina.gregor@vivantes.de</email>
    </contact>
    <investigator>
      <last_name>Steffen Behrens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vivantes Neukölln</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martina Gregor</last_name>
      <email>martina.gregor@vivantes.de</email>
    </contact>
    <investigator>
      <last_name>Harald Darius, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kliniken der Ruhr-Universität Bochum</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bärbel Buchwald</last_name>
      <email>baerbel.buchwald@bergmannsheil.de</email>
    </contact>
    <investigator>
      <last_name>Lars Maier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christof Schmid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sigrun Fechner</last_name>
      <email>sigrun.fechner@uk-erlangen.de</email>
    </contact>
    <contact_backup>
      <last_name>Christine Ücker</last_name>
      <email>christine.uecker@uk-erlangen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Stefan Achenbach, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Weyand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle (Saale)</name>
      <address>
        <city>Halle (Saale)</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathrin Ludwig</last_name>
      <email>kathrin.ludwig@uk-halle.de</email>
    </contact>
    <investigator>
      <last_name>Hendrik Treede, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitäres Herzzentrum Hamburg (UHZ)</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moritz Seiffert, MD</last_name>
      <phone>+49 (0) 40 7410 53979</phone>
      <email>m.seiffert@uke.de</email>
    </contact>
    <investigator>
      <last_name>Ulrich Schäfer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lenard Conradi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albertinen Herz- und Gefäßzentrum Hamburg</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Cramer</last_name>
      <email>eva.cramer@albertinen.de</email>
    </contact>
    <investigator>
      <last_name>Friedrich Christian Rieß, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joachim Schofer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Doreen Brehm</last_name>
      <email>doreen.brehm@uksh.de</email>
    </contact>
    <contact_backup>
      <last_name>Petra Röthgen</last_name>
      <email>petra.roethgen@uksh.de</email>
    </contact_backup>
    <investigator>
      <last_name>Norbert Frey</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jochen Cremer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LMU Klinikum der Universität München</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Schreiber</last_name>
      <email>Melanie.Schreiber@med.uni-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Julinda Mehilli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Hagl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erika Jäger</last_name>
      <email>erika.jaeger@klinik.uni-regensburg.de</email>
    </contact>
    <investigator>
      <last_name>Lars Maier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christof Schmid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uta Dichristin</last_name>
      <email>uta.dichristin@uniklinik-ulm.de</email>
    </contact>
    <investigator>
      <last_name>Wolfgang Rottbauer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andreas Liebold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2017</study_first_submitted>
  <study_first_submitted_qc>April 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2017</study_first_posted>
  <last_update_submitted>October 17, 2017</last_update_submitted>
  <last_update_submitted_qc>October 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aortic Valve Stenosis</keyword>
  <keyword>Transcatheter Aortic Valve Replacement</keyword>
  <keyword>Surgical aortic valve replacement</keyword>
  <keyword>Intermediate operative risk</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

